Mydecine Reports Financial Results for the Second Quarter of Fiscal Year 2022
August 15, 2022 21:46 ET
|
Mydecine Innovations Group Inc.
DENVER, Aug. 15, 2022 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) ("Mydecine" or the "Company"), a biotechnology company aiming to transform the treatment of...
Mydecine Files Full Patent Application Covering MYCO-006 Family of Novel Short-Acting MDMA Analogs
July 19, 2022 07:00 ET
|
Mydecine Innovations Group Inc.
DENVER, July 19, 2022 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), a biotechnology company aiming to transform the...
U.S. FDA Clears MYCO-001 for Multi-Site Government Funded Trial in Smoking Cessation
June 17, 2022 07:00 ET
|
Mydecine Innovations Group Inc.
DENVER, June 17, 2022 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), a biotechnology aiming to transform the treatment of mental...
Mydecine Provides Company Update; Welcomes New Board Member
June 09, 2022 07:00 ET
|
Mydecine Innovations Group Inc.
DENVER, June 09, 2022 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), a biotechnology company aiming to transform the...
Mydecine Announces First Quarter 2022 Financial Results and Highlights
May 16, 2022 21:28 ET
|
Mydecine Innovations Group Inc.
DENVER, May 16, 2022 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), a biotechnology company aiming to transform the treatment...
Mydecine Reports Financial Results for the Fiscal Year 2021 and Provides a Business Update
March 31, 2022 22:03 ET
|
Mydecine Innovations Group Inc.
MYCO-001 Smoking Cessation Clinical Trial Moves Forward Following Conditional IRB Approval Company Advances IP Portfolio With New Patent Applications Covering Novel Molecule Families DENVER, March ...
Mydecine Receives Conditional IRB Approval for Phase 2b Smoking Cessation Study
March 24, 2022 07:30 ET
|
Mydecine Innovations Group Inc.
DENVER, March 24, 2022 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company’), a biotechnology company aiming to transform the...
Mydecine To Attend March Investor Conferences
March 03, 2022 07:30 ET
|
Mydecine Innovations Group Inc.
DENVER, March 03, 2022 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), a biotechnology company aiming to transform the...
Mydecine Reports Positive Pre-IND Meeting With FDA For MYCO-001 Smoking Cessation Study
March 01, 2022 07:30 ET
|
Mydecine Innovations Group Inc.
DENVER, March 01, 2022 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), a biotechnology company aiming to transform the treatment of...
Mydecine Announces MYCO-005 Family of Improved Safety Microdose Novel Molecules
February 16, 2022 07:30 ET
|
Mydecine Innovations Group Inc.
DENVER, Feb. 16, 2022 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), a biotechnology company aiming to transform the...